Literature DB >> 11787071

Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences.

Shigeyuki Kon1, Yasuyuki Yokosaki, Masahiro Maeda, Tatsuya Segawa, Yuko Horikoshi, Hiroe Tsukagoshi, Mohammod M Rashid, Junko Morimoto, Manabu Inobe, Noriharu Shijubo, Ann F Chambers, Toshimitsu Uede.   

Abstract

Osteopontin (OPN) is a secreted protein that has been implicated in diverse physiological and pathological processes. OPN can bind to integrins, via GRGDS or SVVYGLR amino acid sequences, and to other cell surface receptors, and many of OPN's functions are likely mediated via cell adhesion and subsequent signaling. Here we developed and characterized a series of five monoclonal antibodies, raised to distinct internal peptide sequences of human OPN, and have used these sequence-specific reagents, along with the previously described anti-OPN monoclonal antibody mAb53, to map functional epitopes of OPN that are important to cell adhesion and migration. All antibodies were reactive with native as well as recombinant human OPN. One antibody (2K1) raised against the peptide VDTYDGRGDSVVYGLRS could inhibit RGD-dependent cell binding to OPN, with an efficacy comparable to that of mAb53. Furthermore, 2K1 could inhibit alpha9 integrin-dependent cell binding to OPN. The epitope recognized by 2K1 was not destroyed by thrombin digestion, whereas mAb53 has been shown to be unable to react with OPN following thrombin cleavage. The two distinct epitopes defined by 2K1 and mAb53 antibodies are closely related to the SVVYGLR cell-binding domain and the GLRSKS containing thrombin cleavage site, respectively, and are involved in cell binding and cell migration. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11787071     DOI: 10.1002/jcb.10039

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  16 in total

1.  Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer.

Authors:  Alison L Allan; Rosamma George; Sharon A Vantyghem; Mark W Lee; Nicole C Hodgson; C Jay Engel; Ron L Holliday; David P Girvan; Leslie A Scott; Carl O Postenka; Waleed Al-Katib; Larry W Stitt; Toshimitsu Uede; Ann F Chambers; Alan B Tuck
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

2.  Overexpression of osteopontin and integrin αv in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis.

Authors:  Jian Guang Lu; Yong Li; Liang Li; Xuan Kan
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-19       Impact factor: 4.553

3.  Plasma osteopontin levels are elevated in non-ST-segment elevation acute coronary syndromes.

Authors:  Selçuk Coskun; Enver Atalar; Ercan Ozturk; Bunyamin Yavuz; Necla Ozer; Hakan Goker; Kenan Ovünç; Serdar Aksöyek; Sirri Kes; Bulent Sivri; Serafettin Kirazli; Ferhan Ozmen
Journal:  J Natl Med Assoc       Date:  2006-11       Impact factor: 1.798

4.  Antigen-specific induction of osteopontin contributes to the chronification of allergic contact dermatitis.

Authors:  Anne M Seier; Andreas C Renkl; Guido Schulz; Tanja Uebele; Anca Sindrilaru; Sebastian Iben; Lucy Liaw; Shigeyuki Kon; Toshimitsu Uede; Johannes M Weiss
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

5.  Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis.

Authors:  Nobuchika Yamamoto; Fumihiko Sakai; Shigeyuki Kon; Junko Morimoto; Chiemi Kimura; Harumi Yamazaki; Ikuko Okazaki; Nobuo Seki; Takashi Fujii; Toshimitsu Uede
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

6.  Peptide-based vaccination against OPN integrin binding sites does not improve cardio-metabolic disease in mice.

Authors:  Nicole G Grün; Karin Strohmeier; Veronica Moreno-Viedma; Marie Le Bras; Christine Landlinger; Karina Zeyda; Bettina Wanko; Lukas Leitner; Günther Staffler; Maximilian Zeyda; Thomas M Stulnig
Journal:  Immunol Lett       Date:  2016-09-14       Impact factor: 3.685

7.  Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis.

Authors:  Michel S Beausoleil; Erika B Schulze; David Goodale; Carl O Postenka; Alison L Allan
Journal:  BMC Cancer       Date:  2011-01-19       Impact factor: 4.430

8.  Tertiary structure prediction and identification of druggable pocket in the cancer biomarker - Osteopontin-c.

Authors:  Subramaniam Sivakumar; Sivasitambaram Niranjali Devaraj
Journal:  J Diabetes Metab Disord       Date:  2014-01-08

9.  Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells In Vitro and Mouse Experimental Autoimmune Encephalomyelitis In Vivo.

Authors:  Elena Boggio; Chiara Dianzani; Casimiro Luca Gigliotti; Maria Felicia Soluri; Nausicaa Clemente; Giuseppe Cappellano; Erika Toth; Davide Raineri; Benedetta Ferrara; Cristoforo Comi; Umberto Dianzani; Annalisa Chiocchetti
Journal:  J Immunol Res       Date:  2016-07-13       Impact factor: 4.818

10.  Inhibition of Cellular Adhesion by Immunological Targeting of Osteopontin Neoepitopes Generated through Matrix Metalloproteinase and Thrombin Cleavage.

Authors:  Alexander Jürets; Marie Le Bras; Günther Staffler; Gesine Stein; Lukas Leitner; Angelika Neuhofer; Matteo Tardelli; Edvin Turkof; Maximilian Zeyda; Thomas M Stulnig
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.